| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/27/2008 | WO2007119185A3 Degradable therapeutic delivery device |
| 03/27/2008 | WO2007114921A3 Pharmaceutical formulations: salts of 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one and treatment methods using the same |
| 03/27/2008 | WO2007107328A3 Subcutaneous implants containing a degradation-resistant polylactide polymer and a lh-rh analogue |
| 03/27/2008 | WO2007095341A3 Sterilization of corticosteroids with reduced mass loss |
| 03/27/2008 | WO2007079082A3 Gastric release pulse system for drug delivery |
| 03/27/2008 | WO2007072060A3 Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film |
| 03/27/2008 | WO2007066151A3 Topical compositions for treatment of respiratory disorders |
| 03/27/2008 | WO2006065960A3 Cationic liposomes comprising a charge neutral compound and a cationic phospholipid |
| 03/27/2008 | WO2006052880A8 Synergistic effects of combined administration of mirtazapine and a stimulant compound |
| 03/27/2008 | WO2000071079A3 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 03/27/2008 | US20080076793 Use of an ascomycin for the treatment of blepharitis |
| 03/27/2008 | US20080076712 Before cardiopulmonary bypass surgery or coronary artery bypass grafting; injecting a polypeptide preferential inhibitor of kallikrein, rather than aprotinin |
| 03/27/2008 | US20080075785 Controlled release hydrogel formulation |
| 03/27/2008 | US20080075784 Mixture of drug such as cetirizine and cyclodextrin wherein the drug's dissolution rate has been retarded, or the the cyclodextrin's dissolution rate has been enhanced, or both; improved taste masking of pharmaceutical compositions of unpleasant-tasting drugs and cyclodextrin |
| 03/27/2008 | US20080075783 Gliclazide nanosphere and manufacturing method therefor and application thereof |
| 03/27/2008 | US20080075782 Comprising a stabilizing polyol and a bioactive agent, wherein the composition provides quick release of the bioactive agent after administration; inhalation through the mouth; drug delivery; osteoporosis treatment |
| 03/27/2008 | US20080075781 Making oral dosage form by forming granules comprising oxycodone hydrochloride, alkyl cellulose and polymethacrylate, and drying said granules; improving efficiency and quality of pain management |
| 03/27/2008 | US20080075780 Drug delivery systems based on degradible cationic siloxanyl macromonomers |
| 03/27/2008 | US20080075779 Additives And Methods For Enhancing Active Agent Elution Kinetics |
| 03/27/2008 | US20080075778 Matrix structure comprises the reaction product of at least one cationic polymer such as gelatin, at least one anionic polymer such as chondroitin sulfate, and a binding component, and wherein the binding component is distributed throughout the matrix structure of the microparticle; efficiency |
| 03/27/2008 | US20080075777 Apparatus and methods for preparing solid particles |
| 03/27/2008 | US20080075776 Topical Pharmaceutical Compositions Containing An Antiacne Compound And Antibiotic Compound |
| 03/27/2008 | US20080075775 Tamsulosin controlled-release tablet |
| 03/27/2008 | US20080075774 Treatment and/or prevention of a condition major depressive disorder and nicotine addiction; fewer incidences of and/or reduced severity of seizures associated with the administration of bupropion, as compared to known bupropion compositions |
| 03/27/2008 | US20080075773 Solid oral composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or salt and disintegrant comprising crospovidone, sodium starch glycolate, carboxymethylcellulose sodium, sodium alginate; for administering active agents which are poorly soluble in water or acid sensitive |
| 03/27/2008 | US20080075772 Trisecting, quadrisecting, and a pentasecting score pattern in or on a tablet; psychotherapeutic doxepin hydrochloride; enhanced dosage flexibility |
| 03/27/2008 | US20080075771 Opioid antagonist is released in an amount that reduces effectiveness of opioid when dosage form is crushed; monolithic solidified oral dosage form; hydrophilic polymer such as alkyl cellulose or (meth)acrylic acid (co)polymer; drug delivery; resistant to dissolution in aqueous solutions of ethanol |
| 03/27/2008 | US20080075770 Monolithic solidified oral dosage form comprising a drug such as an opioid and a hydrophilic polymer such as alkyl cellulose or (meth)acrylic acid (co)polymer; dissolution resistant in aqueous solutions of ethanol; drug delivery |
| 03/27/2008 | US20080075769 Psychostimulant containing pharmaceutical composition |
| 03/27/2008 | US20080075768 Opioid antagonist is released to reduce effectiveness of opioid (hydromorphone) when dosage form is crushed; monolithic solidified oral dosage form; hydrophilic polymer such as alkyl cellulose or (meth)acrylic acid (co)polymer; drug delivery; resistant to dissolution in aqueous solutions of ethanol |
| 03/27/2008 | US20080075767 Ibuprofen-containing liquid filled hard capsules |
| 03/27/2008 | US20080075766 First and second compressed portions having a surface area, a horizontal, and a vertical axis and at least one light transmitting coating; surrounded or covered by a translucent or transparent shell; drug delivery |
| 03/27/2008 | US20080075765 Methods and materials for reducing risk of cold and/or flu |
| 03/27/2008 | US20080075764 Synthetic and semi-synthetic three-dimensional bodies, such as liposomes, which antiinflammatory, organ protective and immune regulatory effects; autoimmune diseases |
| 03/27/2008 | US20080075763 Polycationic sterol derivatives as transfection agents |
| 03/27/2008 | US20080075762 Compositions for delivery of drug combinations |
| 03/27/2008 | US20080075760 Water soluble component; fibers comprising natural cellulose, wood pulp; regenerated fibers including rayon; and synthetic fibers including polyethylene terephthalate and polypropylene fibers; feel, skin touch and wiping; water absorption retention property |
| 03/27/2008 | US20080075757 Dispersions of microemulsions in hydrogels for drug delivery |
| 03/27/2008 | US20080075756 Enhancing regeneration of lens cells in mammals after endocapsular extraction by filling a lens capsule bag with an injectable material comprising acrylated polysiloxane; intraocular lenses; cataracts, vision defects; coating lense with viscoelastic hyaluronic acid, cellulose, and/or collagen |
| 03/27/2008 | US20080075755 Macular degeneration, choroidal or retinal neovascularization, or ocular inflammation; administering a poxvirus viral complement interfering protein (VCIP) |
| 03/27/2008 | US20080075754 Compositions and medical devices utilizing bioabsorbable liquid polymers |
| 03/27/2008 | US20080075749 Methods and Compositions for Tissue Augmentation |
| 03/27/2008 | US20080075747 Acidic oil in water emulsion comprising allantoin; emulsifier system of an acidic anionic polylmer such as carbopol and an ethoxylated ether or an ethoxylated ester; cosmetics; storage stability; can further include a carbohydrate polymer that can be polygalactose or polyarabinose |
| 03/27/2008 | US20080075745 Topical pharmaceutical compositions containing ciclopirox or a pharmaceutically acceptable salt thereof |
| 03/27/2008 | US20080075687 Ophthalmic compositions containing a synergistic combination of three polymers |
| 03/27/2008 | US20080075674 Cough Suppressor |
| 03/27/2008 | US20080075673 selected from propane, n-butane, isobutane or 2-methylbutane, used in refrigerants, refrigerators, blowing agents and aerosol propellants; pollution control |
| 03/27/2008 | US20080075672 Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| 03/27/2008 | US20080075671 applying curcumin to an upper third of a nasal cavity of mammals, wherein it is absorbed through a nasal mucosa and transported to the brain of the mammal; treatment of neurodegenrative diseases |
| 03/27/2008 | US20080075670 Admixing a pharmaceutical agent with a foam forming agent; introducing the mixture of into a dispensing device; metered dose, external auditory meatus |
| 03/27/2008 | US20080075669 Drug and a trap; retards the rate of release of the drug from the dosage form when the dosage form has been tampered with; opiods |
| 03/27/2008 | US20080075668 Security Device Using Reversibly Self-Assembling Systems |
| 03/27/2008 | US20080075667 Nanoparticles, nanocapsules and nanogels |
| 03/27/2008 | US20080075657 Forming a biocompatible hydrogel in situ; adding a liquid premix of alkylated chitosan and an oxidized polysaccharide in an aqueous medium into an intervertebral disc, hydrogel induces tissue growth within the disc |
| 03/27/2008 | US20080073239 Injection-Molded Water Soluble Container |
| 03/27/2008 | DE202004021462U1 Vermittels Dosiervorrichtungen dosierbare feste pharmazeutische Darreichungsformen By means of metering dosed solid pharmaceutical dosage forms |
| 03/27/2008 | DE102006050806A1 Antimikrobielle Zusammensetzungen und Wundverbände Antimicrobial compositions and wound dressings |
| 03/27/2008 | DE102006044448A1 Gelartiges Basenpräparat zur Supplementierung von Spurenelementen und Verfahren zu dessen Herstellung Gel-base preparation for supplementation of trace elements and process for its production |
| 03/27/2008 | DE102006044447A1 Gel-like base preparation, useful as bath additive or in aromatherapy, comprises base, gel-forming mixture of polysaccharide and xanthan gum and/or silicic acid and essential oil |
| 03/27/2008 | DE102006044199A1 Producing a storage-stable pharmaceutical product comprises encapsulating an amorphous medicament in a nanostructured organic or inorganic host system |
| 03/27/2008 | DE102006042742A1 Nano-Vehikel für den transkutanen Transport, diese enthaltende Zubereitungen und deren Anwendung Nano vehicle for transcutaneous delivery, compositions containing them and their use |
| 03/27/2008 | DE102006042436A1 Kaugummizubereitungen mit physiologischen Wirkstoffen Chewing gum compositions with physiologically active agents |
| 03/27/2008 | DE102005063371A1 Composition for treating burn and scald wounds, comprises mixture of animal fat or oil and tree resin, promotes healing and reduces pain and edema |
| 03/27/2008 | CA2699184A1 Compositions and methods for ph targeted drug delivery |
| 03/27/2008 | CA2664339A1 Subunguicide, and method for treating onychomycosis |
| 03/27/2008 | CA2664109A1 Use of compositions comprising l-theanine and epigallocatechin gallate in the treatment and prevention of cold and/or influenza |
| 03/27/2008 | CA2664097A1 Edible water-soluble film containing a foam reducing flavoring agent |
| 03/27/2008 | CA2663857A1 Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
| 03/27/2008 | CA2663440A1 Preparation of glassified biological reagents |
| 03/27/2008 | CA2663062A1 Galenic form for the trans-mucosal delivery of active ingredients |
| 03/27/2008 | CA2662919A1 Pharmaceutical compositions containing rosuvastatin calcium |
| 03/27/2008 | CA2662777A1 Methods and systems of delivering medication via inhalation |
| 03/26/2008 | EP1903068A1 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/26/2008 | EP1902718A1 Active foam |
| 03/26/2008 | EP1902714A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 03/26/2008 | EP1902713A1 Pharmaceutical composition containing thiazolidinedione compound |
| 03/26/2008 | EP1902712A1 Use of levo-ornidazole for preparing antiparasitic infection drug |
| 03/26/2008 | EP1902711A1 Oral modified release formulations containing Drospirenon and 8-Prenylnaringenin for use in Hormone Replacement Therapy (HRT) |
| 03/26/2008 | EP1902709A1 Extended release indapamide tablets and their process of manufacture |
| 03/26/2008 | EP1902708A1 Drug comprising stabilized pharmaceutical solid compositions and processes for their preparation |
| 03/26/2008 | EP1902706A1 Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
| 03/26/2008 | EP1902705A1 Injectable pharmaceutical nimesulide solutions |
| 03/26/2008 | EP1902084A2 Biodegradable polymers having a pre-determined chirality |
| 03/26/2008 | EP1901783A1 Gentisic acid for stabilisig 123-i radiopharmaceuticals |
| 03/26/2008 | EP1901767A2 Methods and systems for neural maintenance and regeneration |
| 03/26/2008 | EP1901765A1 Intralesional treatment of psoriasis |
| 03/26/2008 | EP1901749A2 Aerosolized fluoroquinolones and uses thereof |
| 03/26/2008 | EP1901739A2 Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| 03/26/2008 | EP1901736A1 Pharmaceutical composition comprising simvastatin and ezetimibe |
| 03/26/2008 | EP1901733A1 Use of huperzine for disorders |
| 03/26/2008 | EP1901724A1 Percutaneously absorptive ophthalmic preparation comprising epinastine |
| 03/26/2008 | EP1901723A2 Antimicrobial materials |
| 03/26/2008 | EP1901722A1 Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds |
| 03/26/2008 | EP1901721A1 Delayed release or extended-delayed release dosage forms of pramipexole |
| 03/26/2008 | EP1901720A2 Improved dosage forms for movement disorder treatment |
| 03/26/2008 | EP1901719A2 Benzimidazole formulation |
| 03/26/2008 | EP1901718A1 Modified release ticlopidine compositions |
| 03/26/2008 | EP1901717A1 Orally disintegrating powder comprising cilostazol and mannitol |
| 03/26/2008 | EP1901716A2 Method for producing a powder containing xylitol crystal particles with another polyol |
| 03/26/2008 | EP1901715A2 Spray-drying process for producing a dry carnitine powder or granulate |